Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
Beate Schmoele-ThomaAgnieszka M ZarebaQin JiangMohan S MaddurRana DanafAlex MannKingsley EzeJuin Fok-SeangGolam KabirAndrew CatchpoleDaniel A ScottAlejandra C GurtmanKathrin U JansenWilliam C GruberPhilip R DormitzerKena A SwansonPublished in: The New England journal of medicine (2022)
RSVpreF vaccine was effective against symptomatic RSV infection and viral shedding. No evident safety concerns were identified. These findings provide support for further evaluation of RSVpreF vaccine in a phase 3 efficacy study. (Funded by Pfizer; EudraCT number, 2020-003887-21; ClinicalTrials.gov number, NCT04785612.).
Keyphrases